Although Epstein-Barr virus (EBV) is an orally transmitted virus, viral transmission through the oropharyngeal mucosal epithelium is not well understood. In this study, we investigated how EBV traverses polarized human oral epithelial cells without causing productive infection. We found that EBV may be transcytosed through oral epithelial cells bidirectionally, from both the apical to the basolateral membranes and the basolateral to the apical membranes. Apical to basolateral EBV transcytosis was substantially reduced by amiloride, an inhibitor of macropinocytosis. Electron microscopy showed that virions were surrounded by apical surface protrusions and that virus was present in subapical vesicles. Inactivation of signaling molecules critical for macropinocytosis, including phosphatidylinositol 3-kinases, myosin light-chain kinase, Ras-related C3 botulinum toxin substrate 1, p21-activated kinase 1, ADP-ribosylation factor 6, and cell division control protein 42 homolog, led to significant reduction in EBV apical to basolateral transcytosis. In contrast, basolateral to apical EBV transcytosis was substantially reduced by nystatin, an inhibitor of caveolin-mediated virus entry. Caveolae were detected in the basolateral membranes of polarized human oral epithelial cells, and virions were detected in caveosome-like endosomes. Methyl ␤-cyclodextrin, an inhibitor of caveola formation, reduced EBV basolateral entry. EBV virions transcytosed in either direction were able to infect B lymphocytes. Together, these data show that EBV transmigrates across oral epithelial cells by (i) apical to basolateral transcytosis, potentially contributing to initial EBV penetration that leads to systemic infection, and (ii) basolateral to apical transcytosis, which may enable EBV secretion into saliva in EBV-infected individuals.
pstein-Barr virus (EBV) is an oncogenic human herpesvirus causing tumors in B lymphocytes (Burkitt's lymphoma and
Hodgkin's disease) and epithelial cells (nasopharyngeal and gastric carcinoma). Worldwide, about 200,000 new cases of EBVassociated cancer are reported each year. The tissue tropism of EBV in vivo is mainly restricted to B lymphocytes and epithelial cells. Virus infection in B lymphocytes is mainly latent, whereas in epithelial cells, it is lytic, i.e., productive (1) .
EBV infection in B lymphocytes and epithelial cells is initiated by attachment of virions to the cell surface (2, 3) . In B lymphocytes, the EBV glycoprotein gp350/220 plays an important role in virus attachment through binding to the cell surface receptor CD21. Virus entry occurs by endocytosis and subsequent fusion of viral and endosomal membranes, which is mediated by the EBV glycoproteins gHgL, gB, and gp42 (4) (5) (6) (7) (8) . EBV entry into nonpolarized epithelial cells does not require endocytosis of virions, and this process is likely initiated by direct fusion of viral and cell membranes (9, 10) . EBV gHgL interacts with ␣v family integrins in epithelial cells, leading to the fusion of viral and cell membranes (11, 12) . EBV gp350/220 and gp42 may not be required for EBV infection of epithelial cells, in contrast to gHgL and gB, which are essential for virus entry into epithelial cells (2, 8, 9, (13) (14) (15) (16) (17) . EBV BMRF-2 interactions with ␤1 and ␣v family integrins are critical for infection and spread of virus in polarized oropharyngeal epithelial cells (18) (19) (20) (21) .
The oropharyngeal mucosal epithelium is a portal for viral entry in primary EBV infection (22) (23) (24) (25) (26) (27) . Abundant secretion of EBV virions into saliva by EBV-seropositive individuals is well documented (28) (29) (30) (31) (32) , suggesting that the oral epithelium may also play a role in EBV release into saliva and transmission to others.
The oropharyngeal epithelium consists of multiple layers of stratified squamous epithelial cells supported by an underlying layer of fibrous connective tissue, the lamina propria (33) . It has been shown that stratified mucosal epithelia, including the oral mucosal epithelium, have well-developed tight junctions (34) (35) (36) (37) , which initiate development of the distinct polarized apical and basolateral membranes of epithelial cells (38, 39) . The polarization of epithelial cells determines the pathways of viral entry and egress (18, (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . The apical surfaces of monostratified polarized oral epithelial cells and ex vivo multistratified oral epithelium are not highly susceptible to cell-free EBV entry and productive infection (18, 49, 50) . However, cell-free EBV does enter polarized oral epithelial cells from their basolateral membranes, leading to productive infection (18, 49) .
It is well documented that polarized tonsil, endometrial, liver, placental, kidney, and intestinal epithelial cells facilitate rapid transcellular transcytosis of various human viruses, including human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), influenza virus, and poliovirus (38, 39, (51) (52) (53) (54) (55) (56) (57) (58) (59) . Transcytosis of viruses may occur bidirectionally (41, 60) , i.e., from both the apical to the basolateral membranes and the basolateral to the apical membranes, and do so by the following sequential steps: (i) endocytosis of virions into early endosomal and sorting vesicles, (ii) sorting and delivery of virions to basolateral (or apical) vesicles, and (iii) release of virions from the basolateral (or apical) membranes. Viral transcytosis may lead to transport of virions from one membrane to the opposite membrane through the cytoplasm without infecting cells.
with pharmacological inhibitors. First, we determined the nontoxic concentrations of inhibitors in polarized tonsil epithelial cells using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Biotium Inc.). Polarized cells were pretreated for 1 h with nontoxic concentrations of chlorpromazine (20 M) , nystatin (12.5 g/ml), 5-(Nethyl-N-isopropyl)amiloride (20 to 100 M), LY294002 (100 M), rottlerin (100 M), dynasore (40 M) , and ML9 (10 M) (all from Sigma). All drug treatments were performed at both apical and basolateral membranes of polarized cells. After drug treatment, cells were washed and used for transcytosis assays. EBV was added to the upper chambers of inserts with apically and basolaterally oriented cells. After 4 h, basolateral media containing virus were collected and used for qPCR assay.
To determine the effect of drugs on virus attachment, cells were pretreated with chlorpromazine, nystatin, or amiloride for 1 h. Untreated cells served as a control. EBV B95-8 was added to the apical or basolateral membranes for 2 h at 4°C. Cells were washed twice with cold phosphatebuffered saline (PBS), pH 7.2, and cell extracts were prepared with cell lysis solution (5 Prime). One set of untreated cells was trypsinized to remove cell-bound virions (38, 65) . EBV binding was quantitated by qPCR.
Treatment of EBV with antiviral human sera. Prior to transcytosis assays, EBV virions were preincubated with a pool of 4 human serum samples (AS-1, AS-2, AS-3, and AS-4) collected from healthy EBV-positive patients (66) . These serum samples have anti-EBV VCA antibodies and neutralizing activity (66) . As a control, a pool of 2 EBV-negative sera was used. EBV-negative human sera were purchased from Blackhawk BioSystems, Inc., and Wampole Laboratories. Virus-containing media were diluted with EBV-positive or -negative sera at 1:25, 1:50, and 1:100 and incubated at 37°C for 1 h. These virions were then used for apical to basolateral or basolateral to apical transcytosis assays.
Domain-specific cholesterol depletion in apical and basolateral membranes of polarized cells and its effect on EBV entry. For domainspecific cholesterol depletion, polarized cells were treated with 10 mM methyl ␤-cyclodextrin (M␤CD) (Sigma) for 15 min at apical and/or basolateral membranes as described previously (67) . Culture media were collected separately from the upper and lower chambers, and release of membrane cholesterol into culture media was measured using the Amplex red cholesterol assay kit (Life Technologies). After cholesterol depletion, cells were used for EBV entry assays. Cells were incubated with virus added to apical membranes for 1 h at 37°C, and TER was measured. Cells were then trypsinized with 0.25% trypsin (Sigma) and collected for qPCR analysis. Since trypsin removes cell-bound virions, the qPCR assay would detect only virions that had penetrated.
Transfection of cells with siRNAs. The following small interfering RNAs (siRNAs) were purchased from Santa Cruz Biotechnology Inc.: caveolin-1 (sc-29241), clathrin heavy chain (sc-35057), cell division control protein 42 homolog (Cdc42; sc-29256), Rac-1 (sc-36351), Pak1 (sc-29700), ARF6 (sc-43619), and dynamin 1/2 (sc-43736). As controls, unrelated (scrambled) siRNAs (sc-37007) were used (Santa Cruz Biotechnology Inc.). Polarized cells were transfected with siRNAs using lipidbased transfection reagents as described previously (39, 68) . The efficiency of siRNA transfection was confirmed using fluorescein isothiocyanate (FITC)-labeled control siRNA; after 24 h, about 70 to 95% of the cells were positive for siRNA-FITC. Silencing of genes of interest by siRNAs at 48 h posttransfection was confirmed using a Western blot assay with antibodies to caveolin-1, clathrin, Cdc42, ARF6, and dynamin 2 (all from Abcam) and Rac-1 (Santa Cruz Biotech). Polarized cells were extracted, and proteins were separated on 16% SDS-polyacrylamide gels and immunoblotted with appropriate antibodies. Protein bands were visualized using enhanced chemiluminescence detection reagents (Amersham), and equal protein loading was confirmed by detection of ␤-actin (Ambion). Protein expression was quantitated by measuring the intensity of pixels (mean density) in protein bands using ImageJ software.
Confocal immunofluorescence microscopy. For immunofluorescence assays, cells were washed with PBS (pH 7.2), fixed with 4% parafor-maldehyde and 2% sucrose in PBS for 5 min, and then permeabilized with 0.01% Triton X-100 in 4% paraformaldehyde for 5 min. The EBV viral capsid protein p18 was detected with goat anti-p18 antibody (Thermo Scientific). For colocalization of EBV p18 with markers of clathrin and caveolin, cells were exposed to EBV and costained with antibodies to clathrin and caveolin-1 (both from Abcam). Cells were examined by confocal microscopy (Bio-Rad MRC2400).
Determination of EBV copy numbers using a qPCR assay. Total DNA was extracted from culture media using an Archive Pure DNA Cell/ Tissue kit (5 Prime). For qPCR assays (69), 20 ng of DNA was used for amplification of the EBV BZLF1 gene (specific primers: forward, 5=-AAA TTT AAG AGA TCC TCG TGT AA ACA TC-3=; reverse, 5=-CGC CTC CTG TTG CCG CAG AT-3=) and fluorogenic probe {5= (6-carboxyfluorescein [FAM]) ATA ATG GAG TCA ACA TCC AGG CTT GGG C (6-carboxytetramethylrhodamine [TAMRA])-3=}. qPCR analysis was performed using an AB Prism 7900 detection system (Applied Biosystems). Thermocycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, 95°C for 15 s, and 60°C for 1 min for 40 cycles. Each reaction mixture contained 1ϫ TaqMan universal master mix with final concentrations of 5.5 mM MgCl 2 , 200 M deoxynucleoside triphosphates (dNTPs), 20 pmol each of forward and reverse primers, 10 pmol of TaqMan probe, and 0.5 U of Hotstart AmpliTaq Gold (Applied Biosystems) in a 20-l volume in a 384-well plate. Experimental samples were run in quadruplicate, and the mean viral load was calculated. Each run had at least two "no template" controls to check for amplicon contamination. DNA from the Namalwa cell line (American Type Culture Collection), which contains two copies of EBV per cell, was used to generate standard curves (69) .
EBV infectivity assay after viral transcytosis. Infectivity of transcytosed EBV was examined in freshly isolated CD19 ϩ B lymphocytes, which were purified from peripheral blood buffy coats (Pacifica Blood Center) as described in our previous work (50) . Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood of healthy donors using a Ficoll-Paque Plus density gradient (Sigma). B lymphocytes were then isolated by positive selection using anti-CD19 Microbeads (Miltenyi Biotec) and separated in a MACS LS column (Miltenyi Biotec). The purity of B lymphocytes was determined by fluorescence-activated cell sorting (FACS) assay using mouse antibodies to CD20. B lymphocytes with a purity of Ͼ95% were used for experiments. The presence of in vivo EBV infection of B lymphocytes was determined by qPCR assay, and only EBVnegative cells were used for infection of transcytosed EBV from the lower chambers of filter inserts.
B lymphocytes (2 ϫ 10 6 cells per insert) were used for infection by transcytosed EBV from the lower chambers of filter inserts. One set of cells was infected directly with the EBV B95-8 virus that was used for transcytosis. Another set of cells was not infected and was used as a control. After 7 days, infected B lymphocytes were treated or not with 30 ng/ml of PMA to induce the lytic cycle of EBV. PMA-induced B cells were used to measure the expression of the EBV lytic genes BZLF1 and gp350/220 by quantitative reverse transcription-PCR (qRT-PCR) assay. Expression of the latent EBV LMP1 and EBNA1 genes was examined in non-PMA-induced cells. For qRT-PCR, total RNA from each sample was extracted using the RNeasy kit (Qiagen, Valencia, CA) according to the protocols provided by the manufacturer. Reverse transcription reactions were performed using the iScript reverse transcriptase kit from Bio-Rad (Hercules, CA) according to the manufacturer's protocol. The target gene was amplified from cDNA using SYBR green real-time PCR master mix (Life Technologies, Grand Island, NY), a 1 mM concentration of each primer, and 5 l of the cDNA in a total volume of 20 l. The following primers were used: LMP1 (forward, 5=-CAG TCA GGC AAG CCT ATG A-3=; reverse, 5=-CTG GTT CCG GTG GAG ATG A-3=), EBNA1 (forward, 5=-TAC AGG ACC TGG AAA TGG CC-3=; reverse, 5=-TCT TTG AGG TCC ACT GCC G-3=, gp350/220 (forward, 5=-AGA ATC TGG GCT GGG ACG TT-3=; reverse, 5=-ACA TGG AGC CCG GAC AAGT-3=), and BZLF1 (forward, 5=-AAA TTT AAG AGA TCC TCG TGT AAA ACA TC-3=; reverse, 5=-CGC CTC CTG TTG AAG CAG AT-3=). The beta-2-microglobulin gene was used as an internal control (forward, 5=-TGA CTT TGT CAC AGC CCA AGA TA-3=; reverse, 5=-CGG CAT CTT CAA ACC TCC A-3=) (70) . EBV gene expression was calculated by the ⌬⌬CT method (71, 72) .
EBV-induced cell proliferation in B lymphocytes was examined using a bromodeoxyuridine (BrdU) cell proliferation kit (Cell Signaling Technology). Freshly purified B lymphocytes were infected with transcytosed EBV B95-8, and cells were cultured for 7 days. One set of cells was not infected and served as a control. EBV-infected and uninfected cells were treated with BrdU, and BrdU incorporation into newly synthesized DNA was detected by an anti-BrdU mouse monoclonal antibody according to the manufacturer's protocol.
Electron microscopy. Cells were fixed with 2% glutaraldehyde and 4% formaldehyde in 0.1 M sodium cacodylate buffer, pH 7.3. Cells were postfixed with 1% osmium tetroxide alone or with 1.5% potassium ferricyanide followed by 2% uranyl acetate and then dehydrated with ethanol. Cells were embedded in Eponate812 or EmBed812. Ultrathin sections were stained with 2% uranyl acetate and examined at 120 kV in a JEOL 1400 transmission electron microscope.
Statistical analysis. The significance of differences between EBV apical to basolateral and basolateral to apical transcytosis through polarized epithelial cells pretreated with different drugs was determined using the Student t test; P values of Ͻ0.05 were considered significant.
RESULTS
Establishment of a polarized oral epithelial cell model for EBV bidirectional transcytosis. To study EBV bidirectional transcytosis, we established polarized primary tonsil keratinocytes. For apical to basolateral transcytosis experiments, cells were grown on the upper surfaces of Transwell filter inserts, with the apical cell surfaces facing up, and virus was added to the apical surfaces (Fig.  1A) . For basolateral to apical transcytosis, cells were grown on the lower surfaces of filter inserts, with the apical cell surfaces facing the lower chamber and the basal cell surfaces attached to the lower face of the filter inserts as described previously (73) (Fig. 1B) . For this, filter inserts were placed upside down in petri dishes, and cells in 50 l of medium were added to the filter surface. Inserts with cells were incubated for 2 to 3 h at 37°C in 5% CO 2 to allow attachment of cells to the filters. Filter inserts were then placed into 12-well plates in the correct orientation. Attached keratinocytes then formed polarized monolayers with apical membranes facing the lower chamber and the basal membrane attached to the filter insert at its lower surface. Adding virus to the upper chambers of these inserts permitted binding of virions to the basal surface of polarized cells.
After plating, cells were maintained for 10 to 14 days. Cells in each insert were then measured for transepithelial resistance (TER), and one or two inserts from each plate was examined for the presence of tight junctions by confocal and/or electron microscopy. For confocal microscopy, polarized cells were immunostained for the tight junction proteins ZO-1 ( Fig. 1 , right images) and occludin (data not shown). Thus, cell polarity was evaluated by two criteria, and cells were considered fully polarized when (i) electron and/or confocal microscopy showed monostratified epithelium with well-developed tight junctions that formed on the upper or lower faces of filter inserts (Fig. 1 , middle and right images) and (ii) TER values reached 600 to 800 ⍀/cm 2 . After confirmation of cell polarity in each experiment, tonsil epithelial cells were used for EBV transcytosis assays.
Transcytosis of EBV through polarized tonsil epithelial cells is bidirectional. EBV transcytosis was examined in polarized TNSL#2 tonsil epithelial cells for both the apical to basolateral and basolateral to apical directions. We used EBV B95-8, and viral titers were calculated based on encapsidated DNA copy number. EBV concentrations in saliva may vary between 5 ϫ 10 7 and 10 8 per ml (29) , indicating that EBV transmission through saliva may involve high concentrations of salivary virions. Therefore, for transcytosis assays, we used 10 7 virions per insert. Virus was added to the upper chambers of Transwell inserts with either apically or basolaterally oriented polarized epithelial cells. After 1, 2, 3, and 4 h, culture media from the lower chambers were examined for EBV by qPCR. Two hours after incubation, EBV DNA was detected in the lower chambers in the transcytosis assay for the basolateral to apical direction ( Fig. 2A) . At 3 h and 4 h postincubation, EBV DNA was detected in the lower chambers in transcytosis assays for both directions, indicating that EBV transcytosis may occur in both directions. However, EBV transcytosis in the apical to basolateral direction was found to be about 2-fold lower than that in the basolateral to apical direction. Detection of about 10 5 virion DNA copies in the apical to basolateral transcytosis assay and 2 ϫ 10 5 DNA copies in the basolateral to apical transcytosis assay at the 4-h time point suggested that approximately 1% and 2% of total input virions traversed the polarized monolayers in the apical to basolateral and basolateral to apical directions, respectively. However, as the majority of virions could be trapped in the filters (18, 74) , we examined the passage of virions through Transwell inserts in the absence of cells. EBV B95-8 virus at 10 7 DNA copies per insert was added to the upper chambers of inserts without cells, and virions collected from the basolateral chambers were quantified by qPCR. These measurements showed that about 1.1 ϫ 10 6 virion DNA copies were present in the basolateral chambers, indicating that approximately 90% of virions are trapped within the filter pores. Thus, the real efficiencies of EBV transcytosis in the apical to basolateral and basolateral to apical directions are approximately 10 and 20%, respectively.
Next, we compared bidirectional EBV transcytosis in polarized tonsil epithelial cells propagated from 8 independent donors (Fig.  2B ). Apical to basolateral EBV transcytosis was detected in 5 of 8 (62%) epithelial cultures obtained from independent donors. EBV basolateral to apical transcytosis was observed in 6 of 8 (75%) polarized epithelial cultures. The efficiency of viral transcytosis varied between polarized cells obtained from different individuals. Apical to basolateral transcytosis varied between 0.15% and 0.35%, and basolateral to apical transcytosis varied between 0.05% and 1.3%. Interestingly, tonsil cells obtained from one donor (TNSL#7) showed only apical to basolateral transcytosis, and that from another donor (TNSL#5) showed only basolateral to apical transcytosis. In TNSL#6 cells, EBV transcytosis was not detected in either direction. TER was 600 to 800 ⍀/cm 2 in all 8 cell lines (data not shown), indicating that all cells were highly polarized and that the variability in EBV transcytosis was not due to a lack of cell polarity.
The maximum duration of our transcytosis assay was 4 h, a time period insufficient for productive viral infection and secretion of progeny virions. Nevertheless, we also examined transcytosis of UV-inactivated EBV, which should not lead to productive viral infection. UV-exposed and untreated B95-8 viruses were used for apical to basolateral and basolateral to apical transcytosis through polarized tonsil epithelial cells. qPCR data showed that the levels of transcytosis of UV-inactivated and control virions were comparable in both directions (Fig. 2C ), indicating that viral transcytosis occurs in the absence of productive EBV infection.
To determine if the levels of EBV transcytosis are similar across different strains of virus, we compared the transcytosis of the B95-8 and Akata strains through polarized tonsil epithelial cells. Transcytosis of the B95-8 and Akata strains in the apical to baso- lateral and basolateral to apical directions showed that both viral strains undergo bidirectional transcytosis through tonsil epithelial cells (Fig. 2D) .
To confirm that EBV transcytosis is specific for the virus, B95-8 virions were preincubated with a pool of EBV-neutralizing human sera collected from 4 healthy EBV-seropositive individuals (66) . As a control, virions were preincubated with a pool of 2 EBVnegative human sera. These virions were then used for apical to basolateral or basolateral to apical transcytosis. Analysis of transcytosed virions by qPCR showed that EBV-specific sera substantially inhibited (50 to 90%) basolateral to apical transcytosis in a dose-dependent manner. EBV sera also inhibited EBV apical to basolateral transcytosis; however, this inhibition was much weaker (ϳ20%) than inhibition of basolateral to apical viral transcytosis (Fig. 2E) .
Transcytosed EBV is infectious. To examine the infectious activity of transcytosed EBV, transcytosis assays were performed in polarized tonsil keratinocytes using B95-8 virus. After apical to basolateral and basolateral to apical transcytosis, culture media containing transcytosed virus were collected and used for infection of EBV-negative B lymphocytes. One set of B cells was directly infected with the same virus as was used for transcytosis of epithelial cells. For direct infection of B cells, a 2 ϫ 10 5 -DNA copy equivalent of virions was used, which is approximately the number of virions that transcytosed through polarized epithelial cells in our assays. After 7 days, B cells were treated with PMA for 3 days to induce the EBV lytic cycle. Total RNA was isolated and examined for the presence of transcripts of the lytic BZLF1 and gp350/ 220 genes. qRT-PCR assay detected EBV lytic gene expression in B lymphocytes infected with virions transcytosed in both the apical to basolateral and basolateral to apical directions (Fig. 3A) . The infectivity of virions transcytosed in the apical to basolateral direction was approximately 0.7-to 2-fold lower than that of virions transcytosed in the basolateral to apical direction. This reflects the lower level of EBV apical to basolateral transcytosis relative to basolateral to apical transcytosis. B cells directly infected with EBV also showed expression of viral lytic genes, confirming that the virus used for transcytosis was infectious.
In the next set of experiments, we examined infection of B lymphocytes by transcytosed EBV by detecting expression of the viral latent LMP1 and EBNA1 genes and by measuring EBV-induced B cell proliferation. B lymphocytes were infected with B95-8 virus transcytosed in either the apical to basolateral or the basolateral to apical direction. Uninfected B lymphocytes served as controls. After 7 days, half of the culture was used for detection of LMP1 and EBNA1 transcripts, and the other half was used for cell proliferation assays using a BrdU kit. Analysis of LMP1 and EBNA1 expression by qRT-PCR showed that both genes were expressed in B lymphocytes infected with EBV B95-8 virus transcytosed through polarized tonsil epithelial cells (Fig. 3B ). LMP1 and EBNA1 expression was not detected in uninfected B lymphocytes. Proliferation of EBV-infected B lymphocytes was 2.3-fold higher than proliferation of uninfected B cells (Fig. 3C) . Thus, these experiments showed that EBV transcytosed through polarized tonsil epithelial cells infects B lymphocytes and induces their proliferation. Apical to basolateral transcytosis of EBV is initiated by macropinocytosis, whereas basolateral to apical transcytosis of EBV is initiated by caveolin-mediated endocytosis. To study the mechanisms of EBV transcytosis, polarized tonsil epithelial cells were pretreated with nontoxic concentrations of chlorpromazine (20 M) or nystatin (12.5 g/ml), which are inhibitors of clathrin-and caveolin-mediated endocytosis, respectively (75) (76) (77) (78) . In parallel experiments, cells were treated with nontoxic concentrations of amiloride (100 M) (79), which inhibits macropinocytosis. Untreated cells served as a control. After treatment, cells were washed and used for apical to basolateral or basolateral to apical transcytosis assays.
After 1 h of drug treatment and 4 h of viral exposure, the TER of polarized cells was measured (Fig. 4A) . The TER data showed that chlorpromazine and amiloride did not reduce TER; however, nystatin reduced it by about 15%. EBV was added to the upper chambers of apically or basolaterally oriented polarized cells, and after 4 h of incubation, culture media from the lower chambers were collected for qPCR assay. After transcytosis assays, polarized cells were examined for paracellular permeability to validate polarized monolayer integrity (Fig. 4B) . No leakage was detected in any of the drug-treated cells, including those treated with nystatin, indicating the presence of intact tight junctions. One set of cells was also used for viability assays, which showed that drug-treated and control cells had similar values (Fig. 4C) . Altogether, the data indicated that drug treatment and viral inoculation had no toxic effect on the polarized cells.
Culture media collected from the lower chambers were used for detection of EBV by qPCR. Quantitation of transcytosed virions showed that pretreatment of polarized cells with the inhibitor of caveolin-mediated endocytosis nystatin reduced EBV transcytosis in the basolateral to apical direction (about 70%) (Fig. 4D) , indicating that caveolin-mediated endocytosis plays a critical role in EBV basolateral to apical transcytosis. In contrast, chlorpromazine did not reduce EBV transcytosis in either direction; i.e., clathrin-mediated endocytosis did not play a significant role in EBV transcytosis. Amiloride substantially reduced (about 80%) apical to basolateral but not basolateral to apical EBV transcytosis, indicating a critical role for macropinocytosis in apical to basolateral transport of virus. To confirm amiloride-mediated inhibition of EBV apical to basolateral transcytosis, polarized cells were treated with increasing concentrations of amiloride (Fig. 4E) . Measurement of viral transcytosis across these cells showed that amiloride-mediated inhibition of EBV apical to basolateral transcytosis was dose dependent. Similarly, we confirmed nystatin-mediated inhibition of basolateral to apical transcytosis by treating cells with increasing concentrations of nystatin (Fig. 4F) . Basolateral to apical transcytosis assays in these cells showed that nystatin-mediated inhibition of EBV basolateral to apical transcytosis was also dose dependent. Amiloride and nystatin also inhibited apical to basolateral and basolateral to apical transcytosis, respectively, of the EBV Akata strain (data not shown).
To determine whether drug treatment changed virus binding to cell surfaces, polarized cells were pretreated with nystatin, chlorpromazine, or amiloride for 1 h and then washed and incubated with EBV B95-8 virus at the apical or basolateral membrane. As shown in our model (Fig. 1) , virus binding to apical membranes does not require crossing of virions through the Transwell filters. In contrast, in order to reach the basolateral membranes, the virus needs to overcome the filter barrier, which blocks approximately 90% of virions from passing through filter pores. To solve this problem and to establish equal numbers of virions for apical and basolateral binding, we added a 10-fold excess of viral inoculum for basolateral binding. Thus, 10 6 and 10 7 virions were added to the upper chambers of inserts with apically and basolaterally oriented polarized cells, respectively. Cells were incubated at 4°C for 2 h for virus binding. The qPCR results revealed that EBV binding to basolateral membranes was about 2-fold higher than binding to apical membranes. Trypsin treatment of cells stripped surface-bound virions from both apical and basolateral membranes, confirming virus binding to cell membranes. Higher basolateral binding was consistent with the higher rate of basolateral to apical transcytosis. None of the drug pretreatments significantly affected viral binding, demonstrating their role specifically in virus entry (Fig. 4G) .
Characterization of EBV macropinocytosis by electron microscopy. To visualize macropinocytosis of EBV, polarized tonsil epithelial cells were exposed to EBV at their apical membranes for 30 min and then analyzed by electron microscopy. Apically incubated virions were surrounded by membrane protrusions (Fig.  5A , green arrowheads, inset) and membrane invaginations (Fig.  5B, green arrowheads, inset) . Virions were also detected in subapical uncoated endocytic vesicles (Fig. 5B and C, blue arrowheads, inset) of approximately 0.2 to 2.5 m diameter, typical sizes for macropinosomes (80) (81) (82) . Similar electron microscopy data have been obtained for macropinocytosis of other viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), human cytomegalovirus (HCMV), human immunodeficiency virus (HIV), African swine fever virus, and influenza virus (83) (84) (85) (86) (87) . Thus, these ultrastructural features of EBV apical entry are characteristics of EBV macropinocytosis. Association of EBV with clathrin-coated pits of vesicles was not observed.
Effect of macropinocytosis and dynamin inhibitors on EBV transcytosis. Macropinocytosis is a multistep process, and membrane ruffling and protrusion formation are among the initial steps which lead to the generation of macropinosomes containing viral particles (88) (89) (90) (91) (92) (93) (94) (95) . These critical events require induction of complex signaling pathways involving activation of phosphatidylinositol 3-kinases (PI3K), protein kinase C (PKC), and myosin light-chain kinase (MLCK). To better characterize the molecular mechanism of EBV macropinocytosis, polarized cells were pretreated with nontoxic concentrations of the following inhibi- tors: LY294002 (100 M) for PI3K, rottlerin (100 M) for PKC, and ML9 (5 M) for MLCK. Since dynamin may be involved in macropinocytosis, cells were also treated with the dynamin inhibitor dynasore (100 M). Polarized cells were treated with inhibitors for 1 h and then washed and measured for TER. None of the drug treatments caused a reduction in TER (data not shown). Cells were then used for EBV apical to basolateral and basolateral to apical transcytosis assays. qPCR data showed that inhibitors of PI3K and dynamin reduced EBV transcytosis in both directions (Fig. 6A) . However, inhibition of PI3K reduced EBV transcytosis mainly in the apical to basolateral direction, in contrast to dynamin inhibition, which predominantly reduced viral transcytosis in the basolateral to apical direction. Inhibitors of PKC and MLCK reduced EBV apical to basolateral transcytosis (Fig. 6A ), but their effects on basolateral to apical transcytosis were not significant.
Macropinocytosis also requires the activation of Ras-related C3 botulinum toxin substrate 1 (Rac-1), p21-activated kinase-1 (Pak1), ADP-ribosylation factor 6 (ARF6), and cell division control protein 42 homolog (Cdc42). To determine the role of these molecules in EBV transcytosis, polarized tonsil cells were transfected with siRNAs against Rac-1, Pak1, Cdc42, and ARF6. We also used siRNA against dynamin. After 48 h, one set of cells was used for Western blot analysis, which showed silencing of expression of Rac-1, Pak1, Cdc42, ARF6, and dynamin (Fig. 6B) . The next set of cells was used for EBV transcytosis. qPCR analysis of EBV transcytosis showed that silencing of Rac-1, Cdc42, and dynamin reduced both apical to basolateral and basolateral to apical virion transcytosis. Silencing of Pak1 and ARF6 reduced apical to basolateral transcytosis but did not affect basolateral to apical transcytosis (Fig. 6C) .
Although it is well known that actin polymerization plays a critical role in macropinocytosis (94), we were unable to test the role of actin polymerization in EBV transcytosis, as blocking of actin polymerization with cytochalasin B in polarized cells caused rapid depolarization of epithelial cells (data not shown).
Caveolin-mediated endocytosis plays a role in EBV basolateral to apical transcytosis. Above (Fig. 4D) , we showed that pretreatment of polarized cells with a pharmacological inhibitor of caveolin-mediated endocytosis reduced mainly basolateral to apical viral transcytosis and that an inhibitor of clathrin-mediated endocytosis did not reduce EBV transcytosis in either direction. To confirm these findings, we coimmunostained polarized cells fixed 30 min after the start of transcytosis for EBV p18 and clathrin or caveolin-1, which are markers of clathrin-or caveolin-containing endocytic vesicles, respectively (Fig. 7) . Confocal microscopy showed that EBV p18 colocalization with clathrin was not detected in either direction ( Fig. 7A and B, upper images) , indicating that clathrinmediated endocytosis does not play a role in EBV entry from both membranes of polarized cells. In contrast, EBV p18 strongly colocalized with caveolin in the basolateral to apical transcytosis assay (Fig.  7B, lower images) but not in the apical to basolateral assay (Fig. 7A , lower images). These data indicate that virion entry from basolateral membranes is initiated by caveolin-mediated endocytosis leading to basolateral to apical transcytosis of virus.
We then examined the role of caveolin-and clathrin-mediated endocytosis in EBV transcytosis by inactivating caveolin-1 and clathrin heavy-chain expression using an siRNA approach. Polarized cells were transfected with specific siRNAs against the caveolin-1 and clathrin heavy-chain genes or with control siRNAs. Forty-eight hours later, one set of cells was subjected to Western blot analysis for detection of caveolin-1 and clathrin heavy-chain expression. The data showed that specific siRNA transfection led to about 50% and 70% reductions in expression of clathrin heavychain and caveolin-1, respectively (Fig. 8A) . In a second set of cells, EBV transcytosis assays were performed. qPCR data revealed that silencing of the caveolin-1 gene reduced basolateral to apical transcytosis but not apical to basolateral transcytosis (Fig. 8B) . Inactivation of clathrin heavy chain did not cause a significant reduction in EBV transcytosis in either direction.
Caveolae and caveosomes are localized to basolateral membranes, and their depletion inhibits EBV basolateral to apical transcytosis. It has been shown that localization of caveolae and caveosomes in polarized kidney and intestinal epithelial cells is predominantly restricted to basal and lateral membranes (96) . Distribution of caveolin-1 in polarized membranes was also found to be predominantly basolateral (97) and not to play a major role in the apical membrane transport machinery (98) . To determine if EBV basolateral entry occurs via caveolin and caveosomes, EBV was added to basolateral membranes of polarized cells, and after 30 min, cells were fixed and analyzed by transmission electron microscopy. We detected the presence of multiple virions within the intercellular space of lateral membranes (Fig. 9A) . Many virions were attached to the lateral membranes with uncoated invaginations (Fig. 9A, inset and arrowheads; Fig. 9B, inset) . The morphology of these invaginations was similar to that of basolaterally localized caveolae (96) . Moreover, EBV was detected in cytoplasmic endosomes (Fig. 9C, inset) , which might be caveosomes that were generated by virus-bound caveolae. Localization of virions to clathrin-coated pits and vesicles was not detected.
Association of caveolin-1 with cholesterol (99) is critical for caveolin-mediated endocytosis (100). To determine the role of caveolin-mediated endocytosis in EBV transcytosis, polarized oral epithelial cells were subjected to domain-specific depletion of cholesterol. It has been shown that application of methyl ␤-cyclodextrin (M␤CD) to the apical or basolateral membranes of polarized epithelial cells results in the release of cholesterol specifically from the treated membranes (67). M␤CD does not penetrate cells but rather interacts with the cell surface and causes release of membrane cholesterol into the medium (67) . Cells were treated with 10 mM M␤CD at the apical and/or basolateral membranes for 15 min. Analysis of apical and basolateral media showed that M␤CD treatment resulted in the release of cholesterol specifically from the treated membrane and not from the untreated membrane (Fig.  10A) . The TER of M␤CD-treated polarized cells was stable for 2 h after treatment (Fig. 10B ), but after 2 h, it was substantially reduced (data not shown); i.e., the tight junctions of these cells were disrupted. Therefore, we were not able to perform transcytosis assays, which require 4 h of incubation of virus with the intact polarized cells. Due to this restriction, instead of examining transcytosis directly, we examined EBV entry, which does not require longer incubation times. After M␤CD treatment, cells were washed with cold PBS and incubated with EBV at the apical or basolateral membranes for 1 h at 37°C. After 1 h of viral incubation, cells were collected by trypsinization (using 0.25% trypsin), and EBV entry was then measured by qPCR. Depletion of cholesterol from apical membranes did not significantly reduce EBV entry (Fig. 10C) . In contrast, cholesterol depletion from basolateral membranes reduced EBV entry by about 90%, indicating that caveolin-mediated viral endocytosis may play a critical role in EBV basolateral to apical transcytosis. 
DISCUSSION
The current working model of primary EBV entry into the human body suggests that first virus infects oral epithelial cells, and then productive replication of virus in epithelium initiates infection of B lymphocytes, leading to systemic infection (1). However, we reported previously that the apical (mucosal) surface of the intact oral epithelium is resistant to cell-free virus infection (18, 50) , suggesting the existence of an alternative mechanism for EBV transmission across the oral epithelium. Here we report that initial EBV entry into mucosal epithelium might occur by rapid viral transcytosis from apical to basolateral membranes.
EBV transcytosis across oral epithelial cells was found to be a rapid process; i.e., virions crossed polarized tonsil epithelial cells from the apical (mucosal surface) to the basolateral membranes or from basolateral membranes to apical surfaces by transcytosis within 3 to 4 h. This indicates that EBV transcytosis is independent of productive viral infection, a finding that is confirmed by transcytosis of UV-inactivated virus. EBV bidirectional transmigration occurred in keratinocytes obtained from most of the independent donors. The efficiency of transcytosis varied among donors, and some of the cultures supported only unidirectional transcytosis or no transcytosis. This could be due to a lack of viral receptors or determinants for virion binding or entry in the apical or basolateral membranes of polarized cells, which needs to be studied further.
EBV virions transcytosed in both the apical to basolateral and basolateral to apical directions were infectious in EBV-negative 
CD19
ϩ B lymphocytes. Furthermore, transcytosed EBV induced proliferation of CD19 ϩ B lymphocytes, indicating that EBV transcytosis through the oral mucosal epithelium may play a critical role in EBV biology and pathogenesis.
Several lines of evidence presented in this paper support a key role for macropinocytosis in EBV entry from the apical membranes of oral epithelial cells, leading to apical to basolateral transcytosis of virus. We found that pretreatment of polarized oral epithelial cells with amiloride, an inhibitor of macropinocytosis, substantially reduced EBV transcytosis in the apical to basolateral direction. Macropinocytosis is an endocytic pathway that mediates the nonselective uptake of soluble molecules, nutrients, and antigens. Accumulating evidence indicates that macropinocytosis may also play a critical role in the uptake of viruses, including vaccinia virus, HIV, HCMV, herpes simplex virus (HSV), KSHV, adenovirus, ebolavirus, coxsackievirus, and paramyxovirus (41, 60, 85, (93) (94) (95) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) .
Macropinocytosis is initiated by activation of multibranch signaling proteins, which include the GTPases Rac-1, Cdc42, and ARF6 and the protein kinases PI3K, Pak1, PKC, and MLCK (88) (89) (90) (91) (92) (93) (94) (95) . Activation of these molecules modulates actin dynamics, leading to plasma membrane ruffling. These ruffles can be in the form of planar or circular extensions or protrusions or large extrusions (blebs). Indeed, our electron microscopy data showed EBV surrounded by protrusions at the apical surfaces of oral epithelial cells, suggesting that binding of virions to the cell surface may activate signaling molecules, leading to formation of such protrusions or ruffling. Furthermore, EBV was detected in membrane invaginations and subapical vesicles, which could be generated by folding back of membrane protrusions, forming cave-like invaginations and macropinosomes. Similar ultrastructural features have been observed in the macropinocytosis of KSHV, HCMV, HIV, African swine fever virus, and influenza virus (83) (84) (85) (86) (87) . Inhibition of the key players in macropinocytosis-PI3K, PKC, MLCK, Rac-1, Pak1, Cdc42, and ARF6 -with pharmacological agents and/or siRNAs substantially reduced EBV apical to basolateral transcytosis, confirming the role of macropinocytosis in initial EBV apical entry.
Apical to basolateral transcytosis of EBV across polarized cells indicates that separation of virion-containing macropinosomes from apical membranes initiates further delivery of virus to the intracellular endosomal compartments, leading to transcellular migration of EBV toward basolateral membranes. It has been shown that PI3K, PKC, MLCK, Rac-1, Pak1, and dynamin play roles in the closure of macropinosomes and their intracellular trafficking (88) (89) (90) (91) (92) (93) (94) (95) . Reduction in EBV transcytosis through inhibition of these signaling molecules confirmed their roles in the formation of macropinosomes and EBV transcellular migration. We further demonstrated a role for macropinocytosis in virus entry from the apical membrane by inhibiting dynamin. Dynamin may play a direct or indirect role in multiple aspects of macropinocytosis, including modulation of Rac-1 localization, actomyosin contractile activity, closure of circular ruffles, and trafficking of macropinosomes (111, 112) . We found that inhibition of dynamin by dynasore pretreatment and siRNA reduced EBV apical and basolateral transcytosis.
Inhibition of clathrin-mediated endocytosis did not significantly inhibit EBV transcytosis in either direction, consistent with the absence of EBV from clathrin-coated vesicles.
We found that EBV interaction with the basolateral membranes of polarized oral epithelial cells leads to transcytosis of virions to apical membranes, and this pathway of virus transmigration depended on caveolin-mediated viral entry. Inactivation of caveolin by nystatin-mediated sequestration of cholesterol and silencing of caveolin expression with siRNA substantially reduced EBV basolateral to apical transcytosis. Electron microscopy showed the presence of caveolae in the basolateral membranes, and EBV was detected in caveosome-like endosomes. Finally, depletion of basolateral cholesterol, which prevents caveola formation, substantially inhibited EBV entry. Thus, data obtained by three independent approaches were consistent with caveolin-mediated EBV entry at basolateral membranes of oral epithelial cells. A critical role for caveolin and cholesterol in the basolateral to apical transcytosis of polymeric IgA receptor and scavenger receptor BI has been reported (113, 114) .
Dynamin is also a critical player in caveolin-mediated endocytosis (115, 116) . Our data showed that inactivation of dynamin by dynasore and inhibition of dynamin expression by siRNA resulted in a reduction in basolateral to apical transcytosis of EBV. Inhibition of Rac-1 and Cdc42, which are critical for macropinocytosis, also reduced EBV basolateral to apical transcytosis. It has been shown that Rac-1 may play role in internalization of E-cadherin via caveolin-associated endocytosis (117) . Activation of Rac-1 is directly associated with lipid rafts, and although Cdc42 is not directly associated with lipid rafts, it is readily activated by raftassociated moieties (118) . It is possible that Rac-1 and Cdc42 might be involved in caveolin-mediated endocytosis of EBV from basolateral membranes of polarized cells.
Cholesterol-containing lipid rafts play an important role in EBV entry into B lymphocytes (119) , which occurs by endocytosis (9, 10) . Interestingly, EBV entry into nonpolarized epithelial cells was found to be mediated by direct fusion of viral and cellular membranes (9, 10) . We cannot exclude the possibility of EBV entry into polarized cells by direct viral fusion. Although we did not specifically investigate this process in the present work, viral fusion would not lead to transcytosis of uncoated virions through polarized epithelial cells.
It has been well documented that continuous EBV shedding into saliva occurs in EBV-seropositive individuals (29, 120) . Thus, EBV-infected intraepithelial B lymphocytes and epithelial cells may produce viral particles, which may migrate through uninfected oral epithelial cells by basolateral to apical transcytosis, leading to shedding of virions into saliva.
EBV-specific sera reduced EBV apical to basolateral and basolateral to apical transcytosis; however, inhibition of basolateral to apical transcytosis was much stronger than inhibition of apical to basolateral transcytosis. These findings suggest that EBV glycoproteins may not play major roles in viral macropinocytosis from the apical surface of tonsil epithelial cells and that other mechanisms could be involved in this process. It has been reported that tonsil epithelium expresses the Fc receptor FC␥III (121) , which may facilitate apical to basolateral transcytosis of IgG-coated EBV virions. A similar mechanism has been shown for HCMV: the neonatal Fc receptor facilitates apical to basolateral transcytosis of IgG-coated HCMV in placental epithelial cells (56) . Importantly, transcytosed HCMV virions bound with nonneutralizing and low-neutralizing antibodies retained their infectivity. The majority of EBV virions in saliva are coated with antibodies (122); thus, virion-bound IgG may play a role in EBV apical to basolateral transcytosis. It is also possible that EBV envelope-associated phospholipids may trigger macropinocytosis of IgG-uncoated virions, as has been shown for other viral pathogens, including vaccinia and influenza viruses (93, 95, 123) . We anticipate that future studies will better define the roles of Fc receptors and EBV phospholipids in viral apical to basolateral transcytosis. Strong inhibition of basolateral to apical transcytosis by EBV-specific sera supports the notion that viral envelope glycoproteins could be involved in the initiation of caveolin-mediated endocytosis, which is a receptor ligand-dependent process.
We previously showed that the EBV glycoprotein BMRF-2 binds to basolaterally sorted ␤1 and ␣5␤1 integrins and facilitates EBV entry from basolateral membranes of polarized oral epithelial cells, leading to productive infection (18, 21) . Here we show that EBV entry from basolateral membranes may also initiate transcytosis of virions through polarized oral epithelial cells long before the establishment of productive infection, i.e., 2 to 4 h after attachment of virions to basolateral membranes. It is possible that BMRF-2-mediated EBV entry may feed into two separate pathways of intracellular transport, with EBV entry from basolateral membranes leading to (i) delivery of virions to nuclei with initiation of productive infection and (ii) transcytosis of virions to apical membranes. It is well known that integrins are constitutively endocytosed and that ␤1 integrin (including ␣5␤1) endocytosis is predominantly caveolin dependent (124) (125) (126) (127) , which is consistent with caveolin-dependent EBV endocytosis and transcytosis at basolateral membranes of oral epithelial cells. Further study may elucidate the functional role of BMRF-2 in this process. EBV gHgL also binds to ␣v␤5, ␣v␤6, and ␣v␤8 integrins, and this binding triggers fusion of viral membranes with cell membranes, leading to productive infection (11, 12) . As most integrins are sorted to the basolateral membranes of polarized epithelial cells, gHgL-mediated virus entry may also occur from basolateral membranes of oral epithelial cells. We showed approximately 90% inhibition of viral entry by cholesterol depletion. Since herpesvirus fusion may be influenced by the lipid composition of membranes (128, 129) , cholesterol depletion may also lead to a reduction in virus fusion. Accordingly, we cannot rule out gHgLmediated EBV basolateral entry by direct fusion of viral envelopes with cell membranes. The approximately 90% inhibition of EBV basolateral entry by cholesterol depletion may include inhibition of both viral endocytosis and direct viral fusion.
In summary, oral mucosal epithelial cells have a polarized organization that facilitates EBV transcytosis from apical to basolateral and from basolateral to apical membranes. EBV transcellular migration from the apical surfaces of epithelial cells to their basolateral membranes was found to be initiated by macropinocytosis. EBV apical to basolateral transcytosis across oral mucosal epithelium may facilitate delivery of virions to subepithelial B lymphocytes and serve as a key mechanism for primary EBV infection. EBV basolateral to apical transcytosis occurs through formation of caveolae and caveosomal vesicles and leads to secretion of viral progeny from the epithelium into saliva in EBV-infected individuals. Identification of the cellular targets for EBV transcytosis may lead to a better understanding of the biology of EBV infection of oral mucosa, including the molecular mechanisms of initial viral infection and secretion of virus into saliva in EBV-seropositive individuals. Furthermore, specific inactivation of EBV-induced macropinocytosis could be useful for preventing EBV infection in vulnerable risk groups, such as EBV-negative transplant recipients.
